Best Ways to Manage Cisplatin Exposure After Mesothelioma Treatment

This excerpt sheds light on mesothelioma, a challenging cancer affecting the linings of the lungs, abdomen, or heart due to exposure to asbestos.


Doctors often combine various treatments to aid mesothelioma patients, one of which is Hyperthermic Intrathoracic Chemotherapy (HITOC). This method delivers cisplatin directly to the cancer site.

A recent study delved into post-HITOC safety measures, particularly examining how cisplatin exits the body via fluids like blood, urine, and lung secretions. Samples from five HITOC patients were collected pre and post-treatment, along with subsequent days, using ICP-MS to measure cisplatin levels.

Best Ways to Manage Cisplatin Exposure After Mesothelioma Treatment

Following HITOC, cisplatin levels notably surged in body fluids but decreased over the next nine days. Around 59% of cisplatin was eliminated through urine within 48 hourspost-HITOC.

While cisplatin levels in HITOC patients' body fluids were lower than in those receiving intravenous medicine, a substantial amount remained. Thus, post-HITOC patient care demands safety precautions, potentially involving protective clothing and gear for healthcare workers to prevent cisplatin exposure.

This study offers critical insights into cisplatin elimination post-HITOC, aiding doctors and healthcare providers in implementing necessary safety measures for everyone's well-being during mesothelioma treatment.




Larisch C, Markowiak T, Ried M, Nowak D, Hofmann HS, Rakete S. The Excretion of Cisplatin after Hyperthermic Intrathoracic Chemotherapy. Cancers (Basel). 2023;15(19):4872. Published 2023 Oct 6. doi:10.3390/cancers15194872. Link:


Popular posts from this blog

Pleurocentesis (Thoracentesis) Procedure, Risks & Complications

Top Reasons Why Military Personnel Become Easy Target of Mesothelioma

Face Swelling Can Be A Sign for Lung Cancer?